Agios Pharmaceuticals (AGIO) accounting officer sells 5,272 shares

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. reported that Principal Accounting Officer Theodore James Washburn Jr. completed an open-market sale of common stock. On March 3, 2026, he sold 5,272 shares at a price of $28.88 per share and held 868 shares of common stock afterward.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Washburn Theodore James Jr.

(Last) (First) (Middle)

88 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	03/03/2026		S		5,272	D	$28.88	868	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ William Cook, as attorney-in-fact for Theodore James Jr. Washburn	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AGIO report for Theodore James Washburn Jr.?

AGIOS PHARMACEUTICALS, INC. reported that Principal Accounting Officer Theodore James Washburn Jr. sold 5,272 shares of common stock. The transaction was an open-market sale at a price of $28.88 per share on March 3, 2026.

How many AGIO shares did Theodore James Washburn Jr. sell and at what price?

Theodore James Washburn Jr. sold 5,272 shares of AGIOS PHARMACEUTICALS, INC. common stock. The reported sale price was $28.88 per share in an open-market transaction dated March 3, 2026.

What is Theodore James Washburn Jr.’s role at AGIOS PHARMACEUTICALS, INC.?

Theodore James Washburn Jr. serves as Principal Accounting Officer at AGIOS PHARMACEUTICALS, INC. This officer role was identified in the insider transaction report associated with his March 3, 2026 open-market sale of 5,272 common shares.

How many AGIO shares did Theodore James Washburn Jr. hold after the reported sale?

After selling 5,272 shares of AGIOS PHARMACEUTICALS, INC. common stock, Theodore James Washburn Jr. beneficially owned 868 shares. This post-transaction ownership figure was reported as direct ownership in the insider filing.

Was the AGIO insider transaction by Theodore James Washburn Jr. a direct or indirect holding?

The reported AGIOS PHARMACEUTICALS, INC. insider transaction by Theodore James Washburn Jr. involved directly held common stock. The filing classifies the ownership type as direct, with no additional nature-of-ownership description or entity attribution noted.

What transaction code was used for Theodore James Washburn Jr.’s AGIO stock sale?

The insider filing for AGIOS PHARMACEUTICALS, INC. lists transaction code “S” for Theodore James Washburn Jr.’s activity. This code corresponds to a sale in an open market or private transaction, matching the reported 5,272-share sale at $28.88 per share.